Physician profile
Emma J Broadbent
NPI 1578929071
$674.36
in general payments reported to CMS, 2019-2025
14 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Pediatrics (Nurse Practitioner) provider received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.05 · 2022: $40.89 · 2023: $240 · 2024: $155 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $126.32 | 2023 | Mounjaro |
| Cranial Technologies, INC | $97.36 | 2021-2024 | Doc Band |
| Boston Scientific Corporation | $88.58 | 2025 | General - Erectile Dysfunction |
| Ironshore Pharmaceuticals INC. | $86.13 | 2023-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $58.93 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $42.59 | 2023-2024 | Qelbree, Qelbree |
| Phadia US INC. | $37.17 | 2025 | Immunocap |
| Sanofi Pasteur INC. | $30.50 | 2024 | |
| Alk-Abello, INC | $25.19 | 2023 | Ragwitek, Grastek, Odactra |
| Corium, LLC | $17.28 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.98 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.10 | 2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $15.99 | 2025 | Bexsero, Pediarix, Rotarix |
| Cipher Pharmaceuticals US LLC | $15.24 | 2025 | Natroba, Spinosad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Broadbent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.